Rational design of allosteric inhibitors targeting C797S mutant EGFR in NSCLC: an integrative in silico and in-vitro study
The findings highlight MK1 as a promising candidate for the treatment of NSCLC harbouring the C797S mutation, providing valuable insights for future drug design and development strategies targeting mutant EGFR.
Authors
- Zhixiong He (ORCID: https://orcid.org/0000-0002-4802-3506)
- Feng Yuan (ORCID: https://orcid.org/0000-0001-9979-3853)
- Mahadevi Vitthal Kendre (ORCID: https://orcid.org/0000-0002-6705-7496)
- Jian Wang (ORCID: https://orcid.org/0000-0003-2291-640X)
- Shaowei Dong (ORCID: https://orcid.org/0000-0002-2082-8417)
- Abhinandan Patil
- Kausing Padvi
Institutions
- University of Wisconsin–Madison (US)
- Dr. Babasaheb Ambedkar Marathwada University (IN)
- Southern University of Science and Technology (CN)
- Southern Medical University Shenzhen Hospital (CN)
- D.Y. Patil University (IN)
- Shenzhen Second People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-28
- DOI
- https://doi.org/10.3389/fonc.2025.1590779
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00